Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Status:
Completed
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
This study considers the safety and tolerability of increasing doses of CX-4945 in
combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD) and
the recommended Phase II dose (RP2D), followed by a randomized study that compares antitumor
activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus
cisplatin versus CX-4945 at the combination RP2D with gemcitabine plus cisplatin.